These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 11317252

  • 21. Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors.
    Walker VE, Poirier MC.
    Environ Mol Mutagen; 2007; 48(3-4):159-65. PubMed ID: 17358025
    [No Abstract] [Full Text] [Related]

  • 22. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.
    Luque A, Hulse S, Wang D, Shahzad U, Tanzman E, Antenozzi S, Smith B.
    Infect Control Hosp Epidemiol; 2007 Jun; 28(6):695-701. PubMed ID: 17520543
    [Abstract] [Full Text] [Related]

  • 23. Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.
    Braitstein P, Chan K, Beardsell A, McLeod A, Montaner JS, O'Shaughnessy MV, Hogg RS.
    J Acquir Immune Defic Syndr; 2002 Apr 15; 29(5):547-8. PubMed ID: 11981375
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
    Winston A, McAllister J, Amin J, Cooper DA, Carr A.
    HIV Med; 2005 May 15; 6(3):191-7. PubMed ID: 15876286
    [Abstract] [Full Text] [Related]

  • 26. Severe anoxic hepatic necrosis in an HIV-1-hepatitis C virus-co-infected patient starting antiretroviral triple combination therapy.
    Karras A, Rabian C, Zylberberg H, Hermine O, Duchatelle V, Durand F, Valla D, Viard JP.
    AIDS; 1998 May 07; 12(7):827-9. PubMed ID: 9619823
    [No Abstract] [Full Text] [Related]

  • 27. Anti-HIV effects of nelfinavir reported after ten months of combination therapy.
    AIDS Patient Care STDS; 1997 Aug 07; 11(4):289-90. PubMed ID: 11361848
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Lamivudine for the treatment of HIV.
    Kumar PN, Patel P.
    Expert Opin Drug Metab Toxicol; 2010 Jan 07; 6(1):105-14. PubMed ID: 20001611
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.
    Antivir Ther; 2004 Apr 07; 9(2):197-204. PubMed ID: 15134181
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Apr 07; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
    Prescrire Int; 2004 Oct 07; 13(73):180-2. PubMed ID: 15499699
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.